| SAN MATEO, Calif., March 30, 2012 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that it has entered into a definitive agreement to sell 3.6 million shares of its common stock at a price per share of $0.40 for aggregate gross proceeds of $1.44 million. In addition, each investor will also receive three-fourths of a warrant to purchase an additional share of common stock at an ini...continued NLTX Healthcare Drugs |
Friday, March 30, 2012
Nile Therapeutics, Inc. to Raise $1.4 Million in Registered Direct Offering
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment